Pre-made Talquetamab benchmark antibody ( Bispecific mAb, anti-GPRC5D;CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Talquetamab biosimilar, Bispecific mAb, Anti-GPRC5D;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Talquetamab is a humanized IgG4PAA bispecific antibody designed to target G protein-coupled receptor family C group 5-member D (GPRC5D) and the CD3 molecule found on T lymphocytes (T cell).
| Products Name (INN Index) | Pre-Made Talquetamab biosimilar, Bispecific mAb, Anti-GPRC5D;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
|---|---|
| INN Name | Talquetamab |
| Target | GPRC5D,CD3E |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Genmab,Janssen Research & Development |
| Conditions Approved | NA |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | GPRC5D,CD3E |
| Package |
